Physician profile
Tara Wood
NPI 1265980528
$7,635.86
in general payments reported to CMS, 2019-2025
22 companies · $4,400 in 2025
The $4,400 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $525 · 2022: $334 · 2023: $821 · 2024: $1,556 · 2025: $4,400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,304 · Travel and Lodging: $2,404 · Education: $68.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,304.49 |
| Travel and Lodging | $2,404.07 |
| Education | $68.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,730.09 | 2022-2025 | Intellis Adaptivestim, Inceptiv, Accurian |
| Abbvie INC. | $704.33 | 2023-2025 | |
| Novo Nordisk INC | $631.27 | 2021-2025 | Wegovy, Ozempic |
| Glaxosmithkline, LLC. | $356.36 | 2022-2025 | Arexvy, Trelegy Ellipta |
| Abbott Laboratories | $326.33 | 2024 | Eterna |
| Allergan, INC. | $322.25 | 2021-2022 | |
| Si-Bone, INC. | $258.32 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $237.82 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $177.04 | 2025 | Relistor |
| Globus Medical, INC. | $151.11 | 2025 | Senza |
| Pfizer INC. | $138.46 | 2022-2025 | |
| Painteq LLC | $111.64 | 2024 | Painteq |
| Neuronetics, INC. | $103.01 | 2023-2024 | Neurostar Tms Therapy System |
| Nevro Corp. | $98.51 | 2024 | Senza |
| Teva Pharmaceuticals USA, INC. | $55.50 | 2021-2024 | Ajovy |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $41.26 | 2024-2025 | Zepbound, Jardiance, Mounjaro |
| Lundbeck LLC | $40.74 | 2025 | Vyepti |
| Protega Pharmaceutials INC | $38.28 | 2025 | Roxybond |
| Collegium Pharmaceutical, INC. | $35.87 | 2024-2025 | Jornay Pm, Xtampza |
| Tonix Medicines, INC. | $34.92 | 2025 | Tonmya |
| Braeburn INC. | $28.41 | 2024 | Brixadi |
| Corcept Therapeutics | $14.34 | 2025 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Wood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.